Status:
ACTIVE_NOT_RECRUITING
CAREMM-2306: Advanced Immunotherapy vs. Classical Immunotherapy
Lead Sponsor:
Seoul St. Mary's Hospital
Conditions:
Lymphoma
Eligibility:
All Genders
19+ years
Brief Summary
The goal of this retrospective study is to compare between the case cohort and control cohort. The case cohort consists of lymphoma patients treated with novel immunotherapy regimen including Chimeri...
Detailed Description
1. Primary endpoints Comparison of survival time by treatment between two groups 2. Secondary endpoints 2.1 Comparison of progression-free survival between two groups 2.2 Comparison of response rates ...
Eligibility Criteria
Inclusion
- Patients diagnosed with malignant lymphoma at Catholic Yeouido St. Mary's Hospital and Seoul St. Mary's Hospital between May 2009 and June 2023.
- Age 19 or older.
- Anti-cancer salvage chemotherpay for the treatment of relapsed/refractory lymphoma.
Exclusion
- Patients suffering from acute leukemia.
- Patients additionally diagnosed with solid cancer (colon cancer, lung cancer, stomach cancer, etc.) during treatment.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT06202885
Start Date
October 1 2023
End Date
December 31 2025
Last Update
January 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul St. Mary's Hospital, The Catholic University of Korea
Seoul, South Korea, 06591